“…These unique properties of prime editing are based on the delivery of a prime editor (PE), consisting of a Cas9-reverse transcriptase fusion protein (hereafter referred to as PE2), along with the prime editing guide RNA (pegRNA) that specifies both the genomic target as well as the desired edit to be written directly into the genome. Prime editing has tremendous potential for treatment of disease-causing mutations, as well as generation of disease models, both in vitro and in vivo ( Schene et al, 2020 ; Jang et al, 2021 ; Kim et al, 2021 ; Liu et al, 2021 ; Park et al, 2021 ; Petri et al, 2021 ; Qian et al, 2021 ). However, the use of prime editing is currently challenged by low efficacy, leading to time-consuming optimization and/or screening approaches in order to achieve satisfactory editing activities ( Liu et al, 2020 ; Schene et al, 2020 ; Chemello et al, 2021 ; Kim et al, 2021 ; Petri et al, 2021 ).…”